Theriva Biologics, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Theriva Biologics amended its 2020 Stock Incentive Plan on August 3, 2026, increasing the maximum shares available for grant by 2,000,000 shares, from 4,500,000 to 6,500,000 shares of common stock. The amendment is subject to stockholder approval. No specific grants, recipient names, vesting schedules, or exercise prices are disclosed in this document.
Why this rating
Equity pool expansion of 44% signals likely near-term dilution for existing shareholders at a $3.9M market-cap micro-cap. Material relative to company size.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.